Synta Pharma Home



Elesclomol

Mechanism |  Presentations |  References |  Meetings

Program Overview

About Elesclomol

Elesclomol is a first-in-class, investigational drug candidate that triggers apoptosis (programmed cell death) in cancer cells. Cancer cells operate at high levels of reactive oxygen species (ROS), or oxidative stress. Elesclomol is believed to act by increasing the level of oxidative stress in cancer cells even further, beyond sustainable levels, inducing apoptosis. This mechanism of action, called oxidative stress induction, represents a novel way of selectively targeting and killing cancer cells.

In preclinical models elesclomol showed potent anti-cancer activity against a broad range of cancer cell types, as well as an ability to enhance the efficacy of certain chemotherapy agents with minimal additional toxicity. Cancers with elevated levels of reactive oxygen species (ROS) may be the most vulnerable to the oxidative stress induction mechanism of elesclomol. Tumor types with high ROS include melanoma, prostate, breast, ovarian, pancreatic, hematologic, and others.

In a 21-center, double-blind, randomized, controlled Phase 2b clinical trial in 81 patients with metastatic melanoma, elesclomol in combination with paclitaxel met the primary endpoint – doubling the median time patients survived without their disease progressing – compared to paclitaxel alone (p= 0.035).

In November 2007, Synta announced that it had initiated a global, pivotal Phase 3 clinical trial ( SYMMETRYSM) in patients with metastatic melanoma, with the same design as the Phase 2b trial. In February 2009, following a review of the independent Data Monitoring Committee that identified possible safety concerns, Synta suspended the SYMMETRY trial as well as other ongoing trials of elesclomol pending further analysis of results. Preliminary results from the SYMMETRY trial were presented at ASCO 2009 in Orlando, Florida. Additional analyses are ongoing, and are expected to be presented later in 2009 or early 2010.

Elesclomol Mechanism of Action

Elesclomol's mechanism of action, oxidative stress induction, has broad potential as a new category of anti-cancer therapy.

In a series of in vitro and in vivo experiments, elesclomol has been shown to rapidly cause an increase in oxidative stress – the level of ROS – inside cancer cells (click here for the publication). This increase in ROS is observed through the measurement of levels of individual reactive oxygen species, such as hydrogen peroxide, directly; or through measuring the increased expression of genes that are induced by the presence of high levels of ROS, including stress proteins such as heat shock protein 70 (Hsp70).

The elevation of ROS inside cancer cells causes a measurable shift in the balance of pro- and anti-apoptotic factors in the cell, including an increase in Bax, a decrease in Bcl-2, and the opening of the mitochondrial pores that allow release of Cytochrome C. These changes make cancer cells more likely to undergo apoptosis and lead to two effects observed in vitro and in vivo: (1) direct apoptosis induction by elesclomol as a single agent, and (2) enhancement of activity of other agents, such as chemotherapies, that act through the intrinsic mitochondrial apoptosis pathway.

Elesclomol-ROS - apoptosis pathway

 

More on ROS and cancer.
References on oxidative stress and cancer.

Presentations

References

Oxidative Stress and Cancer
  • B Ramanathan et al: Resistance to Paclitaxel is Proportional to Cellular Total Antioxidant Capacity, Cancer Research 65: (18), September 2005, 8455-8460.
  • Fruehauf, JP, Meyskens, FL: Reactive Oxygen Species: A Breath of Life or Death? Clinical Cancer Research; 13(3) February 2007, 789-794.
  • Fruehauf, JP, Trapp, V: Reactive oxygen species: an Achilles' heel of melanoma? Expert Review of Anticancer Therapy. 8(11) November 2008, 1751-1757.
  • Gastpar, R., Gehrmann, M., et.al.: Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells. Cancer Res, 2005; 65 (12).
  • Massa, C., et.al.: Enhanced efficacy of tumor cell vaccines transfected with secretable hsp70. Cancer Res, 2004; 64:1502-1508.
  • Noessner, E., et.al.: Tumor-derived heat shock protein 70 peptide complexes are cross-presented by human dendritic cells. J of Immunology, 2002; 169:5424-5432.
  • Pelicano, H et al: ROS stress in cancer cells and therapeutic implications, Drug Resistance Updates 7 (2004) 97-110.
  • Schmitt, E., et.al.: Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy. J of Leukocyte Biology, 2007; Vol 81 (published as DOI 10.1189/jlb.0306167, Aug 2006).
  • Schumacker, PT: Reactive oxygen species in cancer cells: Live by the sword, die by the sword, Cancer Cell, September 2006, 175-176.

[Top of page]

ABOUT |  PIPELINE | CLINICAL TRIALS |  TECHNOLOGY |  INVESTORS  |  CAREERS

Copyright © 2009Synta Pharmaceuticals Corp. All rights reserved. Terms of Use